AU2023210422A1 - Nebulization of fab fragments - Google Patents

Nebulization of fab fragments Download PDF

Info

Publication number
AU2023210422A1
AU2023210422A1 AU2023210422A AU2023210422A AU2023210422A1 AU 2023210422 A1 AU2023210422 A1 AU 2023210422A1 AU 2023210422 A AU2023210422 A AU 2023210422A AU 2023210422 A AU2023210422 A AU 2023210422A AU 2023210422 A1 AU2023210422 A1 AU 2023210422A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
less
galectin
seq
fab fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023210422A
Other languages
English (en)
Inventor
Nathalie HEUZÉ-VOURC'H
Jean-Michel PERCIER
Sebastian VAN DER WONING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Publication of AU2023210422A1 publication Critical patent/AU2023210422A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2023210422A 2022-01-18 2023-01-18 Nebulization of fab fragments Pending AU2023210422A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB202200592 2022-01-18
GB2200592.0 2022-01-18
PCT/EP2023/051073 WO2023139090A1 (en) 2022-01-18 2023-01-18 Nebulization of fab fragments

Publications (1)

Publication Number Publication Date
AU2023210422A1 true AU2023210422A1 (en) 2024-05-23

Family

ID=85036924

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023210422A Pending AU2023210422A1 (en) 2022-01-18 2023-01-18 Nebulization of fab fragments

Country Status (10)

Country Link
US (1) US20250059284A1 (https=)
EP (1) EP4466009A1 (https=)
JP (1) JP2025503701A (https=)
KR (1) KR20240133723A (https=)
CN (1) CN118434440A (https=)
AU (1) AU2023210422A1 (https=)
CA (1) CA3236113A1 (https=)
IL (1) IL314365A (https=)
MX (1) MX2024007659A (https=)
WO (1) WO2023139090A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Also Published As

Publication number Publication date
US20250059284A1 (en) 2025-02-20
WO2023139090A1 (en) 2023-07-27
CA3236113A1 (en) 2023-07-27
KR20240133723A (ko) 2024-09-04
IL314365A (en) 2024-09-01
JP2025503701A (ja) 2025-02-04
MX2024007659A (es) 2024-07-04
EP4466009A1 (en) 2024-11-27
CN118434440A (zh) 2024-08-02

Similar Documents

Publication Publication Date Title
JP7079844B2 (ja) 高濃度抗ｃ５抗体製剤
EP3347377B1 (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
JP7463070B2 (ja) バイオ医薬組成物
IL276234A (en) Antibody formulations
JP6283064B2 (ja) エアロゾルの調製のための方法及び組成物
JP7843248B2 (ja) ＡＰＲＩＬ結合抗体によるＩｇＡ腎症を治療する方法
US20250099386A1 (en) Dry Powder Formulations of Thymic Stromal Lymphopoietin (TSLP)-Binding Antibodies and Methods of Use Thereof
TW202104270A (zh) 包含抗ｃｄ４７／ｐｄ－ｌ１雙特異性抗體的製劑及其製備方法和用途
CN101668773A (zh) 人工程化抗b因子抗体
US20220144937A1 (en) Pharmaceutical composition containing antibody against il-5 and use thereof
EP4375298A1 (en) Pharmaceutical composition of anti-angptl3 antibody or antigen binding fragment thereof and its application
US20250059284A1 (en) Nebulization of fab fragments
EA050653B1 (ru) НЕБУЛИЗАЦИЯ Fab-ФРАГМЕНТОВ
HK40107259A (zh) Fab片段的雾化
TW202529811A (zh) 胸腺基質淋巴細胞生成素（ｔｓｌｐ）結合片段之組成物及其使用方法
HK40096185A (zh) 生物医药组合物
HK40124015A (en) Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
HK40072413A (en) Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof
HK40080447A (en) Biopharmaceutical compositions
HK1251867B (en) Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HEUZE-VOURC'H, NATHALIE; VAN DER WONING, SEBASTIAN AND PERCIER, JEAN-MICHEL